|
US4797368A
(en)
|
1985-03-15 |
1989-01-10 |
The United States Of America As Represented By The Department Of Health And Human Services |
Adeno-associated virus as eukaryotic expression vector
|
|
US5173414A
(en)
|
1990-10-30 |
1992-12-22 |
Applied Immune Sciences, Inc. |
Production of recombinant adeno-associated virus vectors
|
|
US5587308A
(en)
|
1992-06-02 |
1996-12-24 |
The United States Of America As Represented By The Department Of Health & Human Services |
Modified adeno-associated virus vector capable of expression from a novel promoter
|
|
US5846946A
(en)
|
1996-06-14 |
1998-12-08 |
Pasteur Merieux Serums Et Vaccins |
Compositions and methods for administering Borrelia DNA
|
|
EP1108047A1
(en)
|
1998-08-27 |
2001-06-20 |
Aventis Pharma S.A. |
Targeted adenovirus vectors for delivery of heterologous genes
|
|
DE19933719A1
(de)
|
1999-07-19 |
2001-01-25 |
Medigene Ag |
Strukturprotein in Adeno-assoziiertem Virus mit veränderten chromatographischen Eigenschaften, seine Herstellung und Verwendung
|
|
EP1268774A2
(en)
|
2000-03-21 |
2003-01-02 |
Elitra Pharmaceuticals, Inc. |
Identification of essential genes in prokaryotes
|
|
WO2002053703A2
(en)
|
2001-01-05 |
2002-07-11 |
Children's Hospital, Inc. |
Aav2 vectors and methods
|
|
US7749492B2
(en)
*
|
2001-01-05 |
2010-07-06 |
Nationwide Children's Hospital, Inc. |
AAV vectors and methods
|
|
US20040142325A1
(en)
*
|
2001-09-14 |
2004-07-22 |
Liat Mintz |
Methods and systems for annotating biomolecular sequences
|
|
US20050106558A1
(en)
*
|
2001-12-21 |
2005-05-19 |
Luca Perabo |
Library of modified structural genes or capsid modified particles useful for the identification of viral clones with desired cell tropism
|
|
WO2005075506A1
(en)
*
|
2004-01-09 |
2005-08-18 |
The Scripps Research Institute |
Identification of endogenous trimerization domains in the adenovirus fiber protein that allow detargeting and retargeting of viral vectors
|
|
EP2397490B1
(en)
|
2004-07-16 |
2013-09-04 |
THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Vaccine constructs and combinations of vaccines designed to improve the breadth of the immune response to diverse strains and clades of HIV
|
|
US8129352B2
(en)
|
2004-09-16 |
2012-03-06 |
Avi Biopharma, Inc. |
Antisense antiviral compound and method for treating ssRNA viral infection
|
|
US8067571B2
(en)
|
2005-07-13 |
2011-11-29 |
Avi Biopharma, Inc. |
Antibacterial antisense oligonucleotide and method
|
|
WO2007093836A1
(en)
|
2006-02-13 |
2007-08-23 |
Cellectis |
Meganuclease variants cleaving a dna target sequence from a xp gene and uses thereof
|
|
WO2008010009A1
(en)
|
2006-07-18 |
2008-01-24 |
Cellectis |
Meganuclease variants cleaving a dna target sequence from a rag gene and uses thereof
|
|
US9725485B2
(en)
|
2012-05-15 |
2017-08-08 |
University Of Florida Research Foundation, Inc. |
AAV vectors with high transduction efficiency and uses thereof for gene therapy
|
|
WO2009013559A1
(en)
|
2007-07-23 |
2009-01-29 |
Cellectis |
Meganuclease variants cleaving a dna target sequence from the human hemoglobin beta gene and uses thereof
|
|
WO2009019528A1
(en)
|
2007-08-03 |
2009-02-12 |
Cellectis |
Meganuclease variants cleaving a dna target sequence from the human interleukin-2 receptor gamma chain gene and uses thereof
|
|
JP2011512326A
(ja)
|
2007-12-31 |
2011-04-21 |
ナノコア セラピューティクス，インコーポレイテッド |
心不全の治療用のｒｎａ干渉
|
|
US9273296B2
(en)
|
2008-09-08 |
2016-03-01 |
Cellectis |
Meganuclease variants cleaving a DNA target sequence from a glutamine synthetase gene and uses thereof
|
|
ES2738980T3
(es)
|
2008-09-15 |
2020-01-28 |
Childrens Medical Ct Corp |
Modulación de BCL11A para el tratamiento de hemoglobinopatías
|
|
US20110016540A1
(en)
|
2008-12-04 |
2011-01-20 |
Sigma-Aldrich Co. |
Genome editing of genes associated with trinucleotide repeat expansion disorders in animals
|
|
US20110023145A1
(en)
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Genomic editing of genes involved in autism spectrum disorders
|
|
US8592386B2
(en)
|
2008-12-17 |
2013-11-26 |
Sarepta Therapeutics, Inc. |
Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis
|
|
WO2010136549A2
(en)
|
2009-05-28 |
2010-12-02 |
Deutsches Krebsforschungszentrum |
Modified aav capsid polypeptides
|
|
EP2569424A1
(en)
|
2010-05-12 |
2013-03-20 |
Cellectis |
Meganuclease variants cleaving a dna target sequence from the dystrophin gene and uses thereof
|
|
US8198429B2
(en)
|
2010-08-09 |
2012-06-12 |
Avi Biopharma, Inc. |
Antisense antiviral compounds and methods for treating a filovirus infection
|
|
WO2012106725A2
(en)
|
2011-02-04 |
2012-08-09 |
Sangamo Biosciences, Inc. |
Methods and compositions for treating occular disorders
|
|
DK3693025T3
(da)
|
2011-04-22 |
2022-01-10 |
Univ California |
Adenoassocierede virus-virioner med variant capsid og fremgangsmåder til anvendelse heraf
|
|
WO2013082548A1
(en)
|
2011-11-30 |
2013-06-06 |
Sarepta Therapeutics, Inc. |
Oligonucleotides for treating expanded repeat diseases
|
|
WO2013086444A2
(en)
|
2011-12-08 |
2013-06-13 |
Sarepta Therapeutics, Inc. |
Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human lmna
|
|
EP2836226B1
(en)
|
2012-02-24 |
2017-06-28 |
Fred Hutchinson Cancer Research Center |
Compositions and methods for the treatment of hemoglobinopathies
|
|
CA2865011C
(en)
|
2012-02-29 |
2021-06-15 |
Sangamo Biosciences, Inc. |
Methods and compositions for treating huntington's disease
|
|
EP2841572B1
(en)
|
2012-04-27 |
2019-06-19 |
Duke University |
Genetic correction of mutated genes
|
|
EP3470523A1
(en)
*
|
2012-05-09 |
2019-04-17 |
Oregon Health & Science University |
Adeno associated virus plasmids and vectors
|
|
CN105209621B
(zh)
|
2012-12-12 |
2021-05-25 |
布罗德研究所有限公司 |
对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化
|
|
SG10201707569YA
(en)
|
2012-12-12 |
2017-10-30 |
Broad Inst Inc |
Delivery, Engineering and Optimization of Systems, Methods and Compositions for Sequence Manipulation and Therapeutic Applications
|
|
US8697359B1
(en)
|
2012-12-12 |
2014-04-15 |
The Broad Institute, Inc. |
CRISPR-Cas systems and methods for altering expression of gene products
|
|
EP3760720A1
(en)
|
2013-03-14 |
2021-01-06 |
Sarepta Therapeutics, Inc. |
Exon skipping compositions for treating muscular dystrophy
|
|
EP3564379A1
(en)
|
2013-09-13 |
2019-11-06 |
California Institute of Technology |
Selective recovery
|
|
WO2015048577A2
(en)
|
2013-09-27 |
2015-04-02 |
Editas Medicine, Inc. |
Crispr-related methods and compositions
|
|
KR20160097338A
(ko)
|
2013-12-12 |
2016-08-17 |
더 브로드 인스티튜트, 인코퍼레이티드 |
뉴클레오티드 반복 장애에서의 ｃｒｉｓｐｒ-ｃａｓ 시스템의 조성물 및 방법 및 용도
|
|
WO2015116568A2
(en)
*
|
2014-01-28 |
2015-08-06 |
University Of Miami |
Muscle cell-targeting nanoparticles for vaccination and nucleic acid delivery, and methods of production and use thereof
|
|
US11028388B2
(en)
|
2014-03-05 |
2021-06-08 |
Editas Medicine, Inc. |
CRISPR/Cas-related methods and compositions for treating Usher syndrome and retinitis pigmentosa
|
|
CA2943622A1
(en)
|
2014-03-25 |
2015-10-01 |
Editas Medicine Inc. |
Crispr/cas-related methods and compositions for treating hiv infection and aids
|
|
EP3981876A1
(en)
|
2014-03-26 |
2022-04-13 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating sickle cell disease
|
|
WO2015148860A1
(en)
|
2014-03-26 |
2015-10-01 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating beta-thalassemia
|
|
WO2015153791A1
(en)
|
2014-04-01 |
2015-10-08 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating herpes simplex virus type 2 (hsv-2)
|
|
WO2015153789A1
(en)
|
2014-04-01 |
2015-10-08 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating herpes simplex virus type 1 (hsv-1)
|
|
US10577627B2
(en)
*
|
2014-06-09 |
2020-03-03 |
Voyager Therapeutics, Inc. |
Chimeric capsids
|
|
WO2016115543A2
(en)
|
2015-01-16 |
2016-07-21 |
University Of Washington |
Novel micro-dystrophins and related methods of use
|
|
MX2017011004A
(es)
|
2015-02-27 |
2018-02-09 |
Sarepta Therapeutics Inc |
Inclusion del exon2 inducida por antisentido en alfa-glucosidasa.acida.
|
|
JP6836999B2
(ja)
|
2015-03-24 |
2021-03-03 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ |
アデノ随伴ウイルス変異体及びその使用方法
|
|
US11020417B2
(en)
|
2015-06-04 |
2021-06-01 |
Sarepta Therapeutics, Inc |
Methods and compounds for treatment of lymphocyte-related diseases and conditions
|
|
EP3307891B8
(en)
*
|
2015-06-10 |
2019-11-13 |
Association Institut de Myologie |
Combined therapy for duchenne muscular dystrophy
|
|
US10544105B2
(en)
|
2015-07-08 |
2020-01-28 |
Cv6 Therapeutics (Ni) Limited |
Deoxyuridine triphosphatase inhibitors containing cyclopropano linkage
|
|
WO2017040271A1
(en)
|
2015-08-28 |
2017-03-09 |
Sarepta Therapeutics, Inc. |
Modified antisense oligomers for exon inclusion in spinal muscular atrophy
|
|
US20190054113A1
(en)
|
2015-09-30 |
2019-02-21 |
Sarepta Therapeutics, Inc. |
Methods for treating muscular dystrophy
|
|
JP2018530560A
(ja)
|
2015-10-09 |
2018-10-18 |
サレプタ セラピューティクス， インコーポレイテッド |
デュシェンヌ型筋ジストロフィーおよび関連障害の処置のための組成物および方法
|
|
WO2017096164A1
(en)
|
2015-12-02 |
2017-06-08 |
The Board Of Trustees Of The Leland Stanford Junior University |
Novel recombinant adeno-associated virus capsids with enhanced human skeletal muscle tropism
|
|
EA201891419A1
(ru)
|
2015-12-15 |
2019-01-31 |
Сарепта Терапьютикс, Инк. |
Пептид-олигонуклеотидные конъюгаты
|
|
EP3433364A1
(en)
|
2016-03-25 |
2019-01-30 |
Editas Medicine, Inc. |
Systems and methods for treating alpha 1-antitrypsin (a1at) deficiency
|
|
US11060089B2
(en)
|
2016-04-18 |
2021-07-13 |
Sarepta Therapeutics, Inc. |
Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene
|
|
WO2017197355A2
(en)
|
2016-05-13 |
2017-11-16 |
4D Molecular Therapeutics Inc. |
Adeno-associated virus variant capsids and methods of use thereof
|
|
US20230048025A1
(en)
|
2016-12-22 |
2023-02-16 |
Oregon Health & Science University |
Adeno associated viral vectors
|
|
US10055384B2
(en)
|
2016-12-31 |
2018-08-21 |
Entefy Inc. |
Advanced zero-knowledge document processing and synchronization
|
|
EP4219806A3
(en)
|
2017-04-11 |
2023-09-27 |
Ruprecht-Karls-Universität Heidelberg |
Adeno-associated virus library
|
|
US11771662B2
(en)
|
2017-09-05 |
2023-10-03 |
Kansas State University Research Foundation |
Analgesic formulation for control of pain in dogs
|
|
DK3684423T5
(da)
*
|
2017-09-20 |
2024-08-26 |
4D Molecular Therapeutics Inc |
Adeno-associerede virusvariantcapsider og fremgangsmåder til anvendelse deraf
|
|
EA201991450A1
(ru)
|
2017-09-22 |
2019-12-30 |
Сарепта Терапьютикс, Инк. |
Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии
|
|
TW201936201A
(zh)
|
2017-12-14 |
2019-09-16 |
美商堅固生物科技公司 |
基因之非病毒生產及遞送
|
|
JP7374119B2
(ja)
*
|
2018-04-05 |
2023-11-06 |
ジェネトン |
減少した肝臓向性を有するＡＡＶ９とＡＡＶｒｈ７４とのハイブリッド組換えアデノ随伴ウイルス血清型
|
|
CA3097375A1
(en)
*
|
2018-04-27 |
2019-10-31 |
Universitat Heidelberg |
Modified aav capsid polypeptides for treatment of muscular diseases
|
|
IL278598B2
(en)
|
2018-05-11 |
2025-11-01 |
Massachusetts Eye & Ear Infirmary |
Altering tissue tropism of adeno-associated viruses
|
|
US20220096574A1
(en)
|
2019-01-29 |
2022-03-31 |
Holobiome, Inc. |
Methods and compositions for treating and preventing central nervous system disorders and other conditions caused by gut microbial dysbiosis
|
|
CN109897831B
(zh)
|
2019-03-14 |
2021-05-28 |
苏州吉脉基因药物生物科技有限公司 |
具有突变衣壳的腺相关病毒病毒体及其应用
|
|
US20220325296A1
(en)
*
|
2019-09-12 |
2022-10-13 |
The Broad Institute, Inc. |
Engineered adeno-associated virus capsids
|
|
IL291944A
(en)
*
|
2019-10-10 |
2022-06-01 |
Solid Biosciences Inc |
Modified aav capsids and uses thereof
|